NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease
نویسندگان
چکیده
منابع مشابه
Nonalcoholic Fatty Liver Disease Treatment
Nonalcoholic fatty liver disease (NAFLD) is increasing in pediatric age group parallel to the growing prevalence of obesity and overweight all around the world. So changing in life style and interventions on obesogenic environment is cornerstone of NAFLD therapy in obese children. Some experts recommend that children and adolescents be encouraged to follow a low-fat, low-glycemic-index diet t...
متن کاملCirculating Levels of Pro-inflammatory Cytokines in Patients with Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
Background: Pro-inflammatory cytokines are associated with systemic inflammatory responses. Objective: To investigate the levels of pro-inflammatory cytokines (IL-1b, IL-6, and TNF-a) in patients with non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) compared to healthy individuals. Methods: This case-control study was c...
متن کاملLiver visfatin expression in morbidly obese patients with nonalcoholic fatty liver disease undergoing bariatric surgery.
BACKGROUND Visfatin has been identified as a new adipokine with proinflammatory and immunomodulating properties. It seems to interfere with immune and fibrogenic process in nonalcoholic fatty liver disease (NAFLD). The aim was to assess visfatin expression in the liver tissue and its association with biochemical parameters and morphological features in NAFLD patients. MATERIAL AND METHODS The...
متن کاملCitrus auraptene: a potential multifunctional therapeutic agent for nonalcoholic fatty liver disease.
Correspondence and reprint request: Dr. Amirhossein Sahebkar, Pharm.D. Biotechnology Research Center, School of Pharmacy, P.O.Box: 91775-1365 Cardiovascular Research Center Avicenna Research Institute Mashhad University of Medical Sciences Mashhad, Iran E-mail: [email protected] Manuscript received: March 07, 2011. Manuscript accepted: June 24, 2011. October-December, Vol. 10 No.4, 2011:...
متن کاملNovel treatment strategies for patients with nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD), the hepatic manifestation of the metabolic syndrome, affects up to 30% of the population. As with the obesity and diabetes epidemic, NAFLD is a significant public health concern. Compared to other chronic liver diseases, management options for NAFLD are limited. While current treatment focuses on weight loss and management of cardiometabolic risk factor...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Lipids in Health and Disease
سال: 2010
ISSN: 1476-511X
DOI: 10.1186/1476-511x-9-29